Microbial Culture Characteristics and Antimicrobial Susceptibility Patterns Associated with Vesicovaginal Fistula

IF 0.1 Q4 MEDICINE, GENERAL & INTERNAL Majalah Kedokteran Bandung-MKB-Bandung Medical Journal Pub Date : 2022-06-01 DOI:10.15395/mkb.v54n2.2511
Gugum Indra Firdaus, Tjahjodjati Tjahjodjati
{"title":"Microbial Culture Characteristics and Antimicrobial Susceptibility Patterns Associated with Vesicovaginal Fistula","authors":"Gugum Indra Firdaus, Tjahjodjati Tjahjodjati","doi":"10.15395/mkb.v54n2.2511","DOIUrl":null,"url":null,"abstract":"Vesicovaginal fistula (VVF) is commonly linked with recurrent urinary tract infection (UTI). Thus, the patterns of the pathogenic microorganism becomes important consideration in the management of this disease. This study aimed to describe patient profiles, disease etiology, and antimicrobial susceptibility patterns of microorganisms in VVF patients. This retrospective study was conducted on 49 medical records of vesicovaginal fistula patients seen from January 2016 to December 2020. The most prevalent age group of the patients was 40-50 years old. Analysis demonstrated that the leading etiology for VVF among these patients was malignancy (73.47%). The antimicrobial susceptibility was tested using the disc diffusion method and Escherichia coli (44.90%) and Proteus mirabilis (14.29%) were identified as the bacterial pathogens most frequently isolated from urine samples. Of the 39 patients with significant growth of organism cases, 29 (74.35%) had symptomatic UTIs. The isolated gram-negative bacteria had excellent sensitivity to aztreonam, ertapenem, and meropenem, with a more than 90% susceptibility rate, while the gram-positive bacteria had good sensitivity to amikacin, cefepime, tigecycline, aztreonam, ertapenem, and meropenem, with a more than 90% susceptibility. In conclusion, bacterial culture and antibiotic susceptibility test (AST) remains an essential part of managing VVF and their results can be used as a reference for empirical therapy. Amikacin, cefepime, tigecycline, aztreonam, ertapenem, and meropenem should be considered for treatment of UTIs associated with VVF.","PeriodicalId":40791,"journal":{"name":"Majalah Kedokteran Bandung-MKB-Bandung Medical Journal","volume":" ","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Majalah Kedokteran Bandung-MKB-Bandung Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15395/mkb.v54n2.2511","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Vesicovaginal fistula (VVF) is commonly linked with recurrent urinary tract infection (UTI). Thus, the patterns of the pathogenic microorganism becomes important consideration in the management of this disease. This study aimed to describe patient profiles, disease etiology, and antimicrobial susceptibility patterns of microorganisms in VVF patients. This retrospective study was conducted on 49 medical records of vesicovaginal fistula patients seen from January 2016 to December 2020. The most prevalent age group of the patients was 40-50 years old. Analysis demonstrated that the leading etiology for VVF among these patients was malignancy (73.47%). The antimicrobial susceptibility was tested using the disc diffusion method and Escherichia coli (44.90%) and Proteus mirabilis (14.29%) were identified as the bacterial pathogens most frequently isolated from urine samples. Of the 39 patients with significant growth of organism cases, 29 (74.35%) had symptomatic UTIs. The isolated gram-negative bacteria had excellent sensitivity to aztreonam, ertapenem, and meropenem, with a more than 90% susceptibility rate, while the gram-positive bacteria had good sensitivity to amikacin, cefepime, tigecycline, aztreonam, ertapenem, and meropenem, with a more than 90% susceptibility. In conclusion, bacterial culture and antibiotic susceptibility test (AST) remains an essential part of managing VVF and their results can be used as a reference for empirical therapy. Amikacin, cefepime, tigecycline, aztreonam, ertapenem, and meropenem should be considered for treatment of UTIs associated with VVF.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
膀胱阴道瘘的微生物培养特征及耐药性分析
膀胱阴道瘘(VVF)通常与复发性尿路感染(UTI)有关。因此,病原微生物的模式成为管理这种疾病的重要考虑因素。本研究旨在描述VVF患者的患者概况、疾病病因和微生物的耐药性模式。这项回顾性研究对2016年1月至2020年12月期间49例膀胱阴道瘘患者的医疗记录进行了研究。患者中最常见的年龄组是40-50岁。分析表明,在这些患者中,VVF的主要病因是恶性肿瘤(73.47%)。使用纸片扩散法检测抗菌药物敏感性,大肠杆菌(44.90%)和奇异变形杆菌(14.29%)被确定为从尿液样本中最常见的细菌病原体。在39例有明显有机体生长的患者中,29例(74.35%)有症状性尿路感染。分离的革兰氏阴性菌对氨曲南、厄他培南和美罗培南具有良好的敏感性,敏感率超过90%,而革兰氏阳性菌对阿米卡星、头孢吡肟、替加环素、氨曲南,厄他培南和美罗培南具有良好敏感性,敏感度超过90%。总之,细菌培养和抗生素敏感性试验(AST)仍然是治疗VVF的重要组成部分,其结果可作为经验治疗的参考。阿米卡星、头孢吡肟、替加环素、氨曲南、厄他培南和美罗培南应考虑用于治疗与VVF相关的尿路感染。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
34
审稿时长
6 weeks
期刊最新文献
Therapeutic Outcome of High Flow Nasal Cannula (HFNC) for Severe COVID-19 Patients in Isolation Intensive Care Unit Diagnostic Challenge of Adult-onset Type 1 Diabetes Mellitus in a Remote Hospital Effective Visual Media to Increase Knowledge and Comprehension of Multidrug Resistant Tuberculosis Among Patients and Their Caregivers Drug Interactions in Diabetic Ulcer Patients in an Indonesian Private Hospital Effectiveness of WHO Stress Management for Improving Insomnia Severity Index Score in Telegram’s Self-Isolated Online Group Population
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1